Literature DB >> 32476833

Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Remi M M Vanmaris1, Ger T Rijkers1,2.   

Abstract

Sarcoidosis is a systemic inflammatory disease characterized by granulomatous inflammation. The soluble interleukin-2 receptor (sIL-2R) is used as a biomarker for disease severity in sarcoidosis. Moreover, rather than just a biomarker, evidence indicates that sIL-2R could be of biological significance in this disease. The aim of this review is to investigate both its qualities as a biomarker and a potential biological role in sarcoidosis. As a biomarker, the serum level of sIL-2R can be used to distinguish patients from healthy controls, active from inactive disease and to assess treatment success. Additionally, sIL-2R correlates with other biomarkers, including angiotensin-converting enzyme, and with lung function tests and nuclear imaging studies. In sarcoidosis T helper cells and alveolar macrophages are the most likely sources of sIL-2R. While most of the evidence indicates that sIL-2R is generated through proteolytic cleavage of membrane-bound IL-2Rα, no endogenous enzyme has been found to be clearly responsible for sIL-2R formation. It is unclear if sIL-2R has immunostimulatory, immunomodulatory or no functional effects, since conflicting results have been reported. Several potential mechanisms of sIL-2R's biological functions include IL-2 sequestration, prolonging IL-2 half-life, preventing activation of resting T cells or increasing affinity of IL-2Rβ for IL-2. The most likely function of sIL-2R is to modify IL-2 signaling. Increased levels of sIL-2R could either promote disease processes, represent an ineffective attempt to resolve the inflammation or have no effect at all. Further research is required to determine its exact role in the disease and thus its usefulness as a therapeutic target. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 122-129). Copyright:
© 2017.

Entities:  

Keywords:  biomarker; immunopathology; sarcoidosis; soluble interleukin-2 receptor

Year:  2017        PMID: 32476833      PMCID: PMC7170137          DOI: 10.36141/svdld.v34i2.5369

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  66 in total

1.  A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity.

Authors:  Y Jacques; B Le Mauff; F Boeffard; A Godard; J P Soulillou
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

2.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Regulation of interleukin-2 receptor expression and receptor release.

Authors:  T Diamantstein; H Osawa; A Mouzaki; O Josimovic-Alasevic
Journal:  Mol Immunol       Date:  1986-11       Impact factor: 4.407

4.  Microheterogeneity of acute-phase glycoproteins in patients with pulmonary sarcoidosis.

Authors:  P Hrycaj; K Wurm; P Mennet; W Müller
Journal:  Eur Respir J       Date:  1996-02       Impact factor: 16.671

5.  Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation.

Authors:  U Bank; D Reinhold; C Schneemilch; D Kunz; H J Synowitz; S Ansorge
Journal:  J Interferon Cytokine Res       Date:  1999-11       Impact factor: 2.607

6.  Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration.

Authors:  D K Wagner; H L Wong; M K Gately; D L Nelson
Journal:  Cytokine       Date:  1990-09       Impact factor: 3.861

7.  Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients.

Authors:  G Semenzato; C Agostini; L Trentin; R Zambello; M Chilosi; A Cipriani; E Ossi; M R Angi; L Morittu; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis.

Authors:  K Konishi; D R Moller; C Saltini; M Kirby; R G Crystal
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

9.  Soluble interleukin-2 receptor release defect in vitro in elderly subjects.

Authors:  C Caruso; G Di Lorenzo; M A Modica; G Candore; M R Portelli; G Crescimanno; A Ingrassia; G B Sangiorgi; A Salerno
Journal:  Mech Ageing Dev       Date:  1991-06-14       Impact factor: 5.432

10.  Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice.

Authors:  Shane E Russell; Anne C Moore; Padraic G Fallon; Patrick T Walsh
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more
  6 in total

Review 1.  Renal sarcoidosis.

Authors:  Marta Calatroni; Gabriella Moroni; Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2022-06-27       Impact factor: 4.393

Review 2.  Peripheral Markers of Depression.

Authors:  Aleksander Nobis; Daniel Zalewski; Napoleon Waszkiewicz
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

Review 3.  The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Authors:  Daphne Peerlings; Max Mimpen; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2021-09-21

Review 4.  Sarcoid Uveitis: An Intriguing Challenger.

Authors:  Pia Allegri; Sara Olivari; Federico Rissotto; Roberta Rissotto
Journal:  Medicina (Kaunas)       Date:  2022-07-04       Impact factor: 2.948

5.  B-cell lymphoma-associated hemophagocytic lymphohistiocytosis: A case report.

Authors:  Ademola S Ojo; Joseph Asemota; Somtochukwu Ojukwu; Ahmad Rajeh; Amina Bot; Caitlyn J Smith; Katsiaryna Laziuk; Mohammed Saleh
Journal:  Oncol Lett       Date:  2022-06-07       Impact factor: 3.111

6.  Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.

Authors:  Laura E Martínez; Shelly Lensing; Di Chang; Larry I Magpantay; Ronald Mitsuyasu; Richard F Ambinder; Joseph A Sparano; Otoniel Martínez-Maza; Marta Epeldegui
Journal:  Clin Cancer Res       Date:  2021-06-15       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.